Novel uses of combined 5-ht 1a agonists and serotonin reuptake inhibitors
OwnerGerd Bartoszykinventor
Life of this patent
Estimating the term…
Abstract
Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonist, in particular 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbomoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof or 3-{4-[4-(4-cyano-phenyl)-piperazin-1-yl]-butyl}-1H-indole-5-carbonitrile or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment or prophylaxis of self directed traumatic disorders associated with behavioral stressors and compulsive disorders associated with behavioral stressors.
Claims6
Use of compounds being combined selective serotonin (5-HT) reuptake inhibitors (SSRIs) and 5-HT1A receptor agonists for the manufacture of a medicament for use in veterinary medicine for the treatment of disorders associated with behavioral stressors.
Pharmaceutical preparation for the treatment of disorders associated with behavioral stressors for use in veterinary medicine characterized in that it contains at least one compound being combined selective serotonin (5-HT) reuptake inhibitor (SSRI) and 5-HT1A receptor agonist.
Dependencies are inferred from the claim text.